George A Awad

Summary

Affiliation: Humber River Regional Hospital
Country: Canada

Publications

  1. ncbi request reprint Intervention research in psychosis: issues related to the assessment of quality of life
    A G Awad
    Mental Health Program, Humber River Regional Hospital, Toronto, Ontario, Canada
    Schizophr Bull 26:557-64. 2000
  2. pmc Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial
    Georges M Gharabawi
    Medical Affairs, Janssen Pharmaceutica Inc, Titusville, NJ, USA
    BMC Psychiatry 6:45. 2006
  3. doi request reprint Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
    George Awad
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    BMC Psychiatry 14:53. 2014
  4. pmc Does treatment adherence correlates with health related quality of life? Findings from a cross sectional study
    Fahad Saleem
    Department of Pharmacy, University of Baluchistan, Quetta, Pakistan
    BMC Public Health 12:318. 2012
  5. doi request reprint The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia
    A George Awad
    Humber River Hospital, 2175 Keele Street, Room 243A, Toronto, ON, M6M 3Z4, Canada
    CNS Drugs 27:625-36. 2013
  6. doi request reprint Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?
    A George Awad
    Department of Psychiatry and the Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    J Psychopharmacol 26:953-7. 2012
  7. doi request reprint Measuring quality of life in patients with schizophrenia: an update
    A George Awad
    Department of Psychiatry and the Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    Pharmacoeconomics 30:183-95. 2012
  8. pmc Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials
    Clive Elliott Adams
    Cochrane Schizophrenia Group, Academic Department of Psychiatry and Behavioural Sciences, University of Leeds, Leeds, LS2 9LT, UK
    BMC Med 3:15. 2005
  9. ncbi request reprint Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scale
    A George Awad
    Department of Psychiatry, Humber Regional Hospital, 1575 Keele Street, Toronto M6M 3Z4, Canada
    Schizophr Res 70:63-7. 2004
  10. ncbi request reprint Impact of atypical antipsychotics on quality of life in patients with schizophrenia
    A George Awad
    Institute of Medical Science and Department of Psychiatry, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, Canada
    CNS Drugs 18:877-93. 2004

Collaborators

Detail Information

Publications25

  1. ncbi request reprint Intervention research in psychosis: issues related to the assessment of quality of life
    A G Awad
    Mental Health Program, Humber River Regional Hospital, Toronto, Ontario, Canada
    Schizophr Bull 26:557-64. 2000
    ..Unless these issues are adequately clarified and resolved, the recent heightened interest in the concept of quality of life may fade away, and that would be a missed opportunity in the mental health field...
  2. pmc Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial
    Georges M Gharabawi
    Medical Affairs, Janssen Pharmaceutica Inc, Titusville, NJ, USA
    BMC Psychiatry 6:45. 2006
    ..Predictors of patient satisfaction with antipsychotic medication were examined in a study of patients with a recent exacerbation of schizophrenia...
  3. doi request reprint Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
    George Awad
    Department of Psychiatry, University of Toronto, Toronto, ON, Canada
    BMC Psychiatry 14:53. 2014
    ..This analysis evaluated HRQoL changes among patients with schizophrenia switched from their current antipsychotic to lurasidone...
  4. pmc Does treatment adherence correlates with health related quality of life? Findings from a cross sectional study
    Fahad Saleem
    Department of Pharmacy, University of Baluchistan, Quetta, Pakistan
    BMC Public Health 12:318. 2012
    ..The study aimed to evaluate the association between medication adherence and HRQoL...
  5. doi request reprint The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia
    A George Awad
    Humber River Hospital, 2175 Keele Street, Room 243A, Toronto, ON, M6M 3Z4, Canada
    CNS Drugs 27:625-36. 2013
    ..The identification of such a unifying core can prove helpful, not only in the development of appropriate scales, but also in informing and guiding the process of development of new antipsychotics. ..
  6. doi request reprint Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?
    A George Awad
    Department of Psychiatry and the Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    J Psychopharmacol 26:953-7. 2012
    ....
  7. doi request reprint Measuring quality of life in patients with schizophrenia: an update
    A George Awad
    Department of Psychiatry and the Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    Pharmacoeconomics 30:183-95. 2012
    ..Both are significantly affected by the illness itself and its treatment...
  8. pmc Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials
    Clive Elliott Adams
    Cochrane Schizophrenia Group, Academic Department of Psychiatry and Behavioural Sciences, University of Leeds, Leeds, LS2 9LT, UK
    BMC Med 3:15. 2005
    ..Quantitative reviews are rare; this one evaluates the effects of chlorpromazine in the treatment of schizophrenia in comparison with placebo...
  9. ncbi request reprint Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scale
    A George Awad
    Department of Psychiatry, Humber Regional Hospital, 1575 Keele Street, Toronto M6M 3Z4, Canada
    Schizophr Res 70:63-7. 2004
    ....
  10. ncbi request reprint Impact of atypical antipsychotics on quality of life in patients with schizophrenia
    A George Awad
    Institute of Medical Science and Department of Psychiatry, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, Canada
    CNS Drugs 18:877-93. 2004
    ....
  11. ncbi request reprint The burden of schizophrenia on caregivers: a review
    A George Awad
    Department of Psychiatry and the Institute of Medical Science, University of Toronto, Humber River Regional Hospital, Toronto, Ontario, M6M 3Z4, Canada
    Pharmacoeconomics 26:149-62. 2008
    ....
  12. ncbi request reprint New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off?
    A George Awad
    University of Toronto, Institute of Medical Science, Ontario
    Can J Psychiatry 49:297-302. 2004
    ..This overview reviews the impact of second-generation antipsychotics on less frequently researched outcomes such as medication-adherence behaviour, quality of life, and subjective tolerability in patients with schizophrenia...
  13. ncbi request reprint A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial
    Y D Lapierre
    Royal Ottawa Hospital, Ottawa, Ontario, Canada
    Acta Psychiatr Scand Suppl 358:72-7. 1990
    ..The general safety profile of remoxipride as assessed from clinical chemistry, haematology, and cardiovascular variables suggests that remoxipride in the dose ranges studied can be used safely for the treatment of schizophrenic patients...
  14. pmc Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group
    A G Awad
    Clarke Institute of Psychiatry, Department of Psychiatry, University of Toronto, Ontario, Canada
    J Psychiatry Neurosci 22:244-8. 1997
    ..This study presents an approach for inclusion of quality of life as an outcome measure in the design of clinical trials of new antipsychotic medications...
  15. ncbi request reprint Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group
    A G Awad
    Department of Psychiatry, University of Toronto, Canada
    Prog Neuropsychopharmacol Biol Psychiatry 14:769-77. 1990
    ..In females, there was no difference in baseline prolactin between responders and nonresponders...
  16. ncbi request reprint Cannabis induced dopamine release: an in-vivo SPECT study
    L N Voruganti
    Institute of Medical Science, University of Toronto, Toronto, ON, Canada
    Psychiatry Res 107:173-7. 2001
    ....
  17. ncbi request reprint Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging
    L Voruganti
    Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada
    Neuropsychopharmacology 25:642-50. 2001
    ....
  18. ncbi request reprint The treatment of negative symptoms: a clinical and methodological study
    Y D Lapierre
    Department of Psychiatry, Royal Ottawa Hospital, Ontario, Canada
    Int Clin Psychopharmacol 14:101-12. 1999
    ..In addition, the design of the study provides a methodology that is appropriate to the study of primary negative symptoms in schizophrenia...
  19. ncbi request reprint Neuroleptic dysphoria: towards a new synthesis
    L Voruganti
    Institute of Medical Science, University of Toronto, Toronto, Canada
    Psychopharmacology (Berl) 171:121-32. 2004
    ..Understanding this phenomenon has wide ranging clinical and research implications...
  20. ncbi request reprint Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia
    Lakshmi N P Voruganti
    Institute of Medical Science, University of Toronto, Toronto, Canada
    Schizophr Res 56:37-46. 2002
    ....
  21. doi request reprint New generation antipsychotic drugs and compliance behaviour
    Lakshmi P Voruganti
    McMaster University, Hamilton, Ontario, Canada
    Curr Opin Psychiatry 21:133-9. 2008
    ....
  22. ncbi request reprint Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study
    Lakshmi N P Voruganti
    Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, and Humber River Regional Hospital, Toronto, Ontario, Canada
    Schizophr Res 88:179-86. 2006
    ....
  23. pmc The rational use of medications in acute psychotic presentations -- the case for less is more
    A George Awad
    Department of Psychiatry and the Institute of Medical Science, University of Toronto, and Chief of Psychiatry, Humber River Regional Hospital, Toronto, Ont, Canada
    J Psychiatry Neurosci 31:216. 2006
  24. ncbi request reprint Second-generation antipsychotics: looking beyond efficacy
    A George Awad
    Can J Psychiatry 49:283-4. 2004
  25. ncbi request reprint Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?
    Lakshmi P Voruganti
    Schizophrenia Research Program, McMaster University, Hamilton, Ontario
    Can J Psychiatry 49:285-9. 2004
    ..We review the recent literature on the subject and clarify the relation between neuroleptic-induced dysphoria and EPSEs...